Literature DB >> 16400315

Natalizumab and progressive multifocal leukoencephalopathy: highlights of the International Workshop on JC Virus/PML and Multiple Sclerosis, June 3-4, 2005, Philadelphia PA.

Kenneth L Tyler1, Kamel Khalili.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16400315

Source DB:  PubMed          Journal:  Rev Neurol Dis        ISSN： 1545-2913


× No keyword cloud information.
  3 in total

1.  Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.

Authors:  Emanuelle Bellaguarda; Kian Keyashian; Joel Pekow; David T Rubin; Russell D Cohen; Atsushi Sakuraba
Journal:  Clin Gastroenterol Hepatol       Date:  2015-05-19       Impact factor: 11.382

2.  Therapeutic inflammatory monocyte modulation using immune-modifying microparticles.

Authors:  Daniel R Getts; Rachael L Terry; Meghann Teague Getts; Celine Deffrasnes; Marcus Müller; Caryn van Vreden; Thomas M Ashhurst; Belal Chami; Derrick McCarthy; Huiling Wu; Jin Ma; Aaron Martin; Lonnie D Shae; Paul Witting; Geoffrey S Kansas; Joachim Kühn; Wali Hafezi; Iain L Campbell; David Reilly; Jana Say; Louise Brown; Melanie Y White; Stuart J Cordwell; Steven J Chadban; Edward B Thorp; Shisan Bao; Stephen D Miller; Nicholas J C King
Journal:  Sci Transl Med       Date:  2014-01-15       Impact factor: 17.956

3.  The human alpha defensin HD5 neutralizes JC polyomavirus infection by reducing endoplasmic reticulum traffic and stabilizing the viral capsid.

Authors:  Stephen R Zins; Christian D S Nelson; Melissa S Maginnis; Rahul Banerjee; Bethany A O'Hara; Walter J Atwood
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.